B Alfred Tiono, Jordan L Plieskatt, Alphonse Ouedraogo, Ben Idriss Soulama, Kazutoyo Miura, Edith C Bougouma, Mohammad Naghizadeh, Aissata Barry, Jean Baptiste B Yaro, Sem Ezinmegnon, Noelie B Henry, Ebenezer Ofori, Bright Adu, Susheel K Singh, Augustin Konkobo, Karin Lövgren Bengtsson, Amidou Diarra, Cecilia Carnrot, Jenny M Reimer, Amidou Z Ouedraogo, Moussa Tienta, Carole A Long, Issa N Nebie, Issaka Sagara, Sodiomon B Sirima, Michael Theisen
BACKGROUND: Malaria transmission blocking vaccines aim to interrupt the transmission of malaria from one person to another. METHODS: The candidates, R0.6C and ProC6C, share the Plasmodium falciparum sexual stage antigen, Pfs48/45 "6C" domain. R0.6C utilizes the Glutamate Rich Protein (GLURP) as a carrier and ProC6C includes a second domain (Pfs230-Pro) and a short 36 amino acids CSP sequence. Healthy adults (n = 125) from a malaria endemic area of Burkina Faso were immunized with three intramuscular injections, four weeks apart, of 30 μg or 100 μg R0...
January 30, 2024: Journal of Clinical Investigation